Objective: Serum concentrations of the hepatokine fibroblast growth factor (FGF) 21 are elevated in obesity, type-2 diabetes, and the metabolic syndrome. We asked whether FGF21 levels differ between subjects with metabolically healthy vs. unhealthy obesity (MHO vs. MUHO), opening the possibility that FGF21 is a cross-talker between liver and adipose tissue in MUHO. Furthermore, we studied the effects of chronic FGF21 treatment on adipocyte differentiation, lipid storage, and adipokine secretion. Methods: In 20 morbidly obese donors of abdominal subcutaneous fat biopsies discordant for their whole-body insulin sensitivity (hereby classified as MHO or MUHO subjects), serum FGF21 was quantified. The impact of chronic FGF21 treatment on differentiation, lipid accumulation, and adipokine release was assessed in isolated preadipocytes differentiated in vitro. Results: Serum FGF21 concentrations were more than two-fold higher in MUHO as compared to MHO subjects (457 AE 378 vs. 211 AE 123 pg/ mL; p < 0.05). FGF21 treatment of human preadipocytes for the entire differentiation period was modestly lipogenic (þ15%; p < 0.05), reduced the expression of key adipogenic transcription factors (PPARG and CEBPA, À15% and À40%, respectively; p < 0.01 both), reduced adiponectin expression (À20%; p < 0.05), markedly reduced adiponectin release (À60%; p < 0.01), and substantially increased leptin (þ60%; p < 0.01) and interleukin-6 (þ50%; p < 0.001) release. Conclusions: The hepatokine FGF21 exerts weak lipogenic and anti-adipogenic actions and marked adiponectin-suppressive and leptin and interleukin-6 release-promoting effects in human differentiating preadipocytes. Together with the higher serum concentrations in MUHO subjects, our findings reveal FGF21 as a circulating factor promoting the development of metabolically unhealthy adipocytes.
INTRODUCTION
Fibroblast growth factor (FGF) 21, FGF19 (murine homologue: FGF15), and FGF23 constitute a subfamily of FGFs with hormone-like rather than growth factor functions [1] . In mice, FGF21 is produced by liver, pancreas, skeletal muscle, brown and white adipose tissue, and major stimuli for FGF21 release are fasting and ketogenic diets, cold exposure, and exercise [2] . In murine models of obesity and diabetes, and less evident or even absent in normal mice, pharmacological administration or transgenic overexpression of FGF21 exerts beneficial metabolic effects, i.e., reduction of body weight and liver fat, improvement of insulin sensitivity, hyperlipidaemia, and hyperglycaemia, and this is most probably due to the induction of thermogenesis and stimulation of energy expenditure [3e5] . In humans, FGF21's role in physiology and metabolic disease is more complicated and far from being understood: circulating FGF21 is mainly produced by the liver and is independent of nutritional status [1] ; furthermore, its plasma concentrations are elevated in abdominal obesity, fatty liver disease, hyperlipidaemia, insulin resistance, type-2 diabetes, metabolic syndrome, and coronary artery disease [6e10] . Since this is in sharp contrast to data obtained in mice and the existence of a postulated FGF21-resistant state in humans is still insufficiently proven, there is a clear need for further studies to better understand FGF21's role in humans. We previously succeeded in describing metabolically healthy and unhealthy obesity (MHO and MUHO) with hepatic fat content and inflammation representing major determinants of these states [11, 12] . In a very recent metabolomics study, we have shown that human abdominal subcutaneous (hasc) preadipocytes differentiated in vitro to adipocytes reveal intra-and extracellular metabolite signatures that also allow discriminating MUHO from MHO [13] . Thus, these cells reveal stable, mitotically inherited properties that may reflect and/or contribute to these states. In this study, we asked whether serum FGF21 concentrations differ between MHO and MUHO subjects. This would open the possibility that FGF21 acts as a cross-talker between the liver and adipose tissue affecting (pre)adipocyte properties in a way that could explain metabolic features of MUHO versus MHO. Therefore, we studied the effects of chronic FGF21 treatment on typical adipocyte functions, such as adipose conversion, lipid storage, and adipokine secretion, in hasc preadipocytes differentiated in vitro.
MATERIAL AND METHODS

Study participants
The 20 hasc adipose tissue donors reported earlier [13] were morbidly obese (body mass index (BMI) > 40 kg/m 2 all), well matched for gender, age, and body fat content (as measured by bioelectrical impedance), but discordant for their whole-body insulin sensitivity (as estimated by a fivepoint oral glucose tolerance test-derived insulin sensitivity index calculated as 10,000/[fasting glucose {mmol/L} x fasting insulin {pmol/L} x mean glucose {mmol/L} x mean insulin {pmol/L}] 1/2 ). According to their insulin sensitivity, they were stratified into ten MHO (insulin-sensitive; insulin sensitivity index !5.0 Â 10 19 L 2 x mol
À2
) and ten MUHO (insulinresistant; insulin sensitivity index 3.5 Â 10 19 L 2 x mol
) subjects, and the clinical characteristics of the two groups were reported recently [13] . The study adhered to The Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants gave informed written consent to the study, and the study protocol was approved by the local ethics board.
Preadipocyte culture, differentiation, and treatment
Preadipocytes were isolated from the 20 hasc adipose tissue explants as described earlier [14] and expanded in a-MEM/Ham's nutrient mixture F12 (1:1) containing 20% fetal calf serum, 1% chicken embryo extract (Sera Laboratories, Haywards Heath, UK), 100 IU/mL penicillin, 0.1 mg/mL streptomycin, 0.5 mg/mL fungizone, and 2 mmol/L glutamine. Second-pass cells were used for experiments. At confluence, adipose conversion was induced by shifting the cells into DMEM/Ham's nutrient mixture F12 (1:1), 5% fetal calf serum, 17 mmol/L pantothenate, 1 mmol/L biotin, 2 mg/mL apo-transferrin, 1 mmol/L human insulin, 1 mmol/L dexamethasone, 100 IU/mL penicillin, 0.1 mg/mL streptomycin, 0.5 mg/mL fungizone, and 2 mmol/L glutamine (differentiation medium) supplemented with 0.5 mmol/L 3-isobutyl-1-methyl-xanthine, 2 nmol/L triiodo-thyronine, and 50 mmol/L indomethacin for seven days. Thereafter, the cells were allowed to terminally differentiate for another 11 days in differentiation medium alone. Differentiating preadipocytes were left untreated or were chronically treated for the whole 18-day period with 50 ng/mL recombinant human (rh)FGF21 (PeproTech, Rocky Hill, NJ, USA). Culture media and supplements were obtained from Lonza (Basel, Switzerland) and Biochrom (Berlin, Germany).
Staining of intracellular neutral lipids
Differentiation of preadipocytes to adipocytes was qualitatively monitored by microscopy after Oil Red O staining according to Greenberger et al. [15] . For quantification of intracellular neutral lipids, Oil Red O was extracted with isopropanol and photometrically measured at 500 nm as described earlier [16] .
2.4. RNA isolation and real-time quantitative polymerase chain reaction (qPCR) (Pre)adipocytes were harvested with Qiazol lysis reagent (Qiagen, Hilden, Germany). Total RNA was isolated with miRNeasy columns (Qiagen), treated with RNase-free DNase I, and reverse transcribed into cDNA using Qiagen's QuantiTect reverse transcription kit. Real-time qPCR was performed in technical duplicates with QuantiTect primer assays on a LightCyclerÔ 480 II (Roche Diagnostics, Mannheim, Germany). All mRNA data were normalized to the housekeeping gene RPS13 using the DCt method.
2.5. Enzyme-linked immunosorbent assays FGF21 in serum and adiponectin, leptin, interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) in the conditioned cell culture media were measured with immunoassays from R&D Systems (Wiesbaden-Nordenstadt, Germany) according to the manufacturers' instructions. 2.7. Genome-wide gene expression analysis Total RNA was isolated as described. The Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany) was used to assess RNA quality, and only high-quality RNA (RNA integrity number >9) was used for microarray analysis. Total RNA (30 ng) was amplified using the Ovation PicoSL WTA System V2 in combination with the Encore Biotin Module (NuGEN, Leek, The Netherlands). Amplified cDNA was hybridized on Affymetrix Human Gene ST 1.0 arrays (Affymetrix, Santa Clara, CA, USA). Staining (Fluidics script FS450_0007) and scanning was done according to the Affymetrix expression protocol including minor modifications as suggested in the Encore Biotin protocol (NuGEN). Expression console (Affymetrix) was used for quality control and to obtain annotated normalized robust multi-array analysis gene level data (standard settings including sketch-quantile normalization). Statistical analyses were performed by utilizing the statistical programming environment R implemented in CARMAweb [17] . Genewise testing for differential expression was done employing the limma t-test (paired) and Benjamini-Hochberg correction for multiple testing (false discovery rate <10%). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes term and pathway enrichment analyses were performed with GePS (Genomatix, Germany) and significant terms (p < 0.01) were determined. In addition, Ingenuity Pathway Software (http://www.ingenuity.com) was used to identify enriched pathways. Array data have been submitted to GEO (GSE67279).
Further statistical analyses
To approximate normal distribution, serum FGF21 concentrations were log e -transformed prior to statistical analysis. Differences in serum FGF21 between the MHO and MUHO groups were tested by multiple linear regression analysis with FGF21 concentration as outcome variable, the nominal MHO/MUHO classification as independent variable, and gender, age, and BMI as confounding variables. All in vitro data, except microarray data (see above), were analyzed by two-group comparisons (FGF21-treated vs. untreated) using two-tailed paired Student's t-test. A p-value <0.05 was considered statistically significant. For these analyses, the statistical software package JMP 10.0 (SAS Institute, Cary, NC, USA) was used.
RESULTS
FGF21 concentrations in MHO and MUHO subjects
After adjustment for the putative confounders gender, age, and BMI by multiple linear regression modeling, serum FGF21 concentrations were more than twice as high in MUHO subjects as compared to MHO subjects (unadjusted 457 AE 378 vs. 211 AE 123 pg/mL, means AE SD; adjusted data presented in Figure 1 ; p ¼ 0.023).
FGF21 responsiveness of differentiating hasc preadipocytes
The FGF21 receptor complex, composed of FGF receptor-1 and bklotho, was readily detectable on the gene expression level as determined by qPCR (mean Cp-values in undifferentiated preadipocytes: FGFR1 22.8, KLB 33.9). To further provide evidence that hasc preadipocytes are responsive to rhFGF21, differentiating preadipocytes (from day 8 of differentiation) were incubated for 10 min with 50 ng/mL (2.6 nmol/L) rhFGF21, a concentration that is above the physiological range (reported to reach up to 3 ng/mL [1] ), but well within the pharmacological range reported for novel FGF21 analogues/mimetics (17.5e150 ng/mL [18] ), and below the high concentrations usually used in in vitro settings (!1 mg/mL [19e21] ). This acute treatment induced robust phosphorylation of AMPKa, ERK1, and ERK2 (Figure 2 ), well-known FGF21 downstream signaling events [19, 22] . Therefore, we used 50 ng/mL rhFGF21 in all subsequent experiments.
Effect of chronic FGF21 treatment on lipid accumulation
As shown by qualitative Oil Red O staining ( Figure 3A ) and photometric quantification of the intracellular Oil Red O content over time ( Figure 3B ), triglyceride accumulation was significantly increased by rhFGF21 during the early stages of differentiation. This effect, however, was modest (þ15%, days 4 and 8) and diminished to a statistical trend at later time-points (p ¼ 0.09, days 12 and 18; Figure 3B ).
3.4. Effects of chronic FGF21 treatment on white and brown adipocyte marker gene expression Chronic rhFGF21 treatment significantly impaired the expression of the key adipogenic transcription factors peroxisome proliferator-activated receptor-g (PPAR-g; -15%, day 18; Figure 4A ) and CCAAT/ enhancer-binding protein-a (C/EBP-a; up to À40%, days 8e18; Figure 4B ). In addition, rhFGF21 reduced the expression of the adipokine adiponectin (up to À20%; days 4 and 18; Figure 4C ), whereas leptin expression remained unaffected (p > 0.08). Unexpectedly, the brown adipocyte marker genes encoding uncoupling protein-1 (UCP-1), PPAR-g coactivator-1a (PGC-1a), and cell death-inducing DNA fragmentation factor-like effector a (CIDEA) were differently regulated with UCP-1 being 2-fold induced by rhFGF21 (days 12 and 18; Figure 4D ) and PGC-1a and CIDEA being repressed by up to À40% and À50%, respectively (all time-points; Figure 4E ,F). Similar regulations of the brown adipocyte marker genes were seen when rhFGF21 was sub-chronically added for three days to adipocytes (from day 18) that were differentiated in the absence of rhFGF21 (data not shown). It should be noted that the UCP-1 expression levels were very low (mean Cp-value on day 0: 35.9; mean Cp-value on day 18: 31.4). Moreover, we did not obtain higher expression levels using isoproterenol, a wellknown and potent inducer of the gene. Therefore, we concluded that hasc preadipocytes represent a cell type with very limited capacity to brown. In accordance with this, we did not detect any convincing signal for UCP-1 protein by immunocytochemistry.
3.5. Effects of chronic FGF21 treatment on adipokine secretion Secretion of the major adipokines adiponectin, leptin, IL-6, and TNF-a upon chronic treatment with rhFGF21 was assessed in 48-hour conditioned culture media at different time-points after start of differentiation. Adiponectin release into the medium was markedly reduced (up to À60%; days 8 and 18; Figure 5A ), whereas that of leptin (up to þ60%; days 12 and 18; Figure 5B ) and interleukin-6 (up to þ50%; all time-points; Figure 5C ) was substantially increased by rhFGF21 treatment. TNF-a secreted by preadipocytes of day 0 ranged at the detection limit (<5 pg/mL) and became undetectable at later time-points both in the absence and presence of rhFGF21 (data not shown). To see whether the rhFGF21-induced increase in IL-6 release was due to enhanced IL-6 gene expression, we performed qPCR. In accordance with the release data, IL-6 gene expression was induced by rhFGF21 (up to þ45%; days 4, 8, and 18; Figure 5D ). Upon a closer look at the temporal course of adiponectin release, as depicted in Figure 5A , it appeared as if FGF21 not only reduces overall adiponectin release but also alters the shape of the release curve: in the absence of chronic FGF21, adiponectin release appeared biphasic with a prominent peak on day 8 (first phase) and half-maximum levels on day 12 that modestly further declined from day 12 on (second phase); chronic FGF21 treatment changed the curve into a bell-shaped one with a markedly diminished, broader, and delayed peak between days 8 and 12; as a result of this, there is a crossing point of the curves on day 12.
3.6. Role of candidate genes/pathways underlying FGF21-induced adiponectin suppression Adiponectin is a major secretory product of adipocytes and an important insulin-sensitizing adipokine [23] . Therefore, we tried to further decipher the adiponectin-suppressive effect of chronic consequently reduced activity of the adiponectin-inducing transcription factor PPAR-g), the effect size of adiponectin gene repression was modest (À20%) and did not correspond to the marked adiponectin release-suppressive effect of FGF21 (À60% Black bars e rhFGF21-treated cultures; white bars e untreated controls. C/EBP-a e CCAAT/enhancer-binding protein a; CIDEA e cell deathinducing DNA fragmentation factor-like effector a; hasc e human abdominal subcutaneous; PGC-1a e PPAR-g coactivator 1a; PPAR-g e peroxisome proliferator-activated receptor g; qPCR e quantitative polymerase chain reaction; rh e recombinant human; UCP-1 e uncoupling protein 1. *p < 0.05, **p < 0.01, ***p < 0.001.
Ontology and Kyoto Encyclopedia of Genes and Genomes terms did not reveal any significant rhFGF21-induced changes in these pathways (Supplementary Figure S1 , Supplementary Tables S1 and S2 ). This whole-genome gene expression analysis, however, confirmed the IL-6-inducing (þ50%; day 8) and PGC-1a-repressing (À30%; day 8) effects of rhFGF21 (þ49% and À29%; Supplementary Table S1 ). As a second hypothesis, we tested whether the enhanced IL-6 expression of FGF21-treated cells might affect, in an auto-/paracrine mode, adiponectin release. Neither the chronic use of a neutralizing anti-IL-6 antibody nor that of a pharmacological inhibitor of IL-6 signaling (small molecule STAT3 inhibitor stattic) significantly influenced rhFGF21-dependent suppression of adiponectin release (data not shown).
DISCUSSION
In the present study of morbidly obese human subjects, we asked whether FGF21 is a potential cross-talker between the liver, where it originates in humans, and adipose tissue, affecting human (pre) adipocyte properties in a way that may discriminate MUHO from MHO. In humans, FGF21 concentrations in blood directly correlate with BMI, overall body fat mass, visceral fat mass, pericardial fat mass, and ectopic lipid deposition [10,24e31] . On the other hand, anorexia nervosa is associated with lower plasma FGF21 levels [32] , and acute fat loss due to bariatric surgery was also reported to reduce plasma FGF21 [33] . Here we show that circulating FGF21 levels are more than two-fold higher in MUHO as compared to body fat-matched MHO subjects, pointing to an adiposity-independent role of FGF21 in insulin resistance in humans. This is in keeping with previous studies reporting BMI-and body fat mass-independent associations of plasma FGF21 levels with hepatic and whole-body insulin resistance [6, 26, 27] . This finding opened the possibility that pathophysiologically high plasma concentrations of the human hepatokine FGF21, as measured in the morbidly obese subjects of the MUHO group, can exert metabolically detrimental effects and thus may contribute to the MUHO phenotype.
To explore whether chronically elevated concentrations of FGF21 alter human (pre)adipocyte properties, we applied a moderately supraphysiological concentration (50 ng/mL) for 18 days and studied its impact on adipose conversion, lipid storage, and adipokine secretion of differentiating hasc preadipocytes. We detected modest lipogenic and anti-adipogenic effects of this treatment. Most impressively however, chronic FGF21 treatment markedly altered the release of the classical adipokines adiponectin, leptin, and IL-6: FGF21 potently suppressed adiponectin release and enhanced leptin and IL-6 release with the effects on adiponectin and IL-6 being, at least in part, reflected by FGF21's impact on the expression of the respective genes. Since the FGF21 concentration used in these experiments is well within the range of pharmacological blood concentrations reached with FGF21 analogues/mimetics [18] , the described unfavorable FGF21 effects on (pre)adipocyte properties could be of particular relevance for the clinical use of these novel compounds currently in development for the treatment of diabetes. Even though the adiponectin-suppressive effect of FGF21 observed in this study is in agreement with results from several human cross-sectional and intervention studies showing an inverse relationship between plasma FGF21 and plasma adiponectin concentrations [29,31e35] , a recent 28-day clinical trial with LY2405319, an FGF21 variant engineered to improve biopharmaceutical properties, revealed treatment-induced elevations of plasma adiponectin [18] . The origin of this discrepancy is unclear but may be due to the structural peculiarities of LY2405319 resulting from the introduction of an additional disulfide bond, deletion of four N-terminal amino acids, and elimination of an O-linked glycosylation site [36] . With respect to physiology and to adiponectin's well-known insulinsensitizing properties, adiponectin suppression by the natural form of human FGF21, as observed in our study in differentiating hasc preadipocytes, could be a possible reason for FGF21's association with insulin resistance in humans. As to the molecular mechanism(s) underlying adiponectin suppression, the observed FGF21-induced repression of adiponectin gene expression may, of course, be relevant. Adiponectin gene repression could, in turn, result from impaired PGC-1a gene expression as PGC-1a is an essential coactivator of the transcription factor PPAR-g, a well-described transcriptional inducer of the adiponectin gene [37, 38] . However, the repressive effect of FGF21 on adiponectin gene expression was modest compared to the FGF21-induced reduction in adiponectin release. Thus, additional mechanisms might contribute to FGF21-dependent adiponectin suppression. In this context, we assessed whether IL-6, which is induced and released upon FGF21 treatment, acts as an auto-/paracrine negative feedback regulator of adiponectin release, as was hypothesized in earlier studies [39, 40] . However, our attempts to interfere with IL-6 signaling were without any effect on adiponectin release. Our results obtained with a neutralizing anti-IL-6 antibody and an inhibitor of IL-6 signaling are certainly insufficient to ultimately exclude a role of adipocyte-derived IL-6 in FGF21-induced adiponectin suppression, and further studies are needed to clarify this issue. Finally, we tested whether adiponectin suppression is due to FGF21-induced alterations in the expression of genes involved in more general pathways, such as protein synthesis, protein degradation, and/or exocytosis. Since our whole-genome microarray analysis was well-powered (N ¼ 20) and did not reveal any significant FGF21 effects on these pathways, we suggest that other, still unknown, mechanisms may contribute to FGF21-dependent adiponectin suppression. Even though mechanistically unresolved, FGF21-induced adiponectin suppression may establish a novel hypothesis as depicted in Figure 6 : fatty liver, a hallmark of MUHO [11, 41] , produces elevated levels of circulating FGF21 [10, 42] . FGF21, in turn, suppresses adiponectin production in adipose tissue as suggested by our data herein, and this is in line with the reduced serum adiponectin levels of our MUHO subjects [11, 13] as well as with the inverse relationship between FGF21 and adiponectin levels observed in several cross-sectional and longitudinal studies [29,31e35] . As FGF21 is repressed by low-and high-molecular-weight forms of adiponectin in primary human hepatocytes [43] and adiponectin knockdown vice versa results in increased hepatic FGF21 expression [44] , FGF21-induced hypoadiponectinaemia may further enhance hepatic FGF21 production and establish a vicious cycle aggravating whole-body insulin resistance. One might argue that a bias of our work is that we do not discuss our data with respect to the wealth of findings about FGF21 in mice. However, we are convinced that such a discussion, against the background of obvious species-specific differences with respect to the sites of FGF21 production, the regulation of FGF21 expression, the relationship of circulating FGF21 levels with pathophysiological states, and certain FGF21 effects (as was recently reviewed in [2] ), is not helpful as long as we do not know the exact molecular basis of these discrepancies. Therefore, the primary focus of our work was to get closer to an understanding of FGF21's role in humans by discussing our human in vivo and in vitro findings in the light of what is known about FGF21 in humans.
CONCLUSIONS
The hepatokine FGF21 exerts weak lipogenic and anti-adipogenic effects and marked adiponectin-suppressive and leptin and interleukin-6 release-promoting effects in cultured hasc adipocytes. Together with the markedly higher serum concentrations in MUHO subjects, our findings point to FGF21 as a circulating factor promoting the development of metabolically unhealthy adipocytes and hypoadiponectinaemia. These metabolically unfavorable FGF21 effects could be of particular relevance for the clinical use of FGF21 analogues/mimetics currently in pharmaceutical development.
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